Methods for diagnosing risk of renal allograft fibrosis and rejection
AssigneeIcahn School of Medicine at Mount Sinai
InventorsBarbara Murphy, Weijia Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method for diagnosing a renal allograft recipient's risk for developing fibrosis of the allograft and allograft loss. The method includes determining the expression levels of certain microRNAs, which have been determined to be predictive of an allograft recipient's risk. Also disclosed herein is a method of treating a renal allograft recipient to inhibit fibrosis of the allograft and allograft loss, as well as kits for use in the methods disclosed herein.
Claims19
A method for diagnosing and treating a renal allograft recipient at risk for developing fibrosis of the allograft and allograft loss, the method comprising:
- (a) determining the expression levels of said microRNAs in a blood sample using Nanostring analysis, wherein the microRNAs are hsa-mir-128, hsa-mir-29b-3p, hsa-mir-302b-3p, and hsa-mir-192-5p;
- (b) determining the expression levels of said microRNAs in a control sample using Nanostring analysis for each microRNA;
- (c) diagnosing the recipient as being at risk for developing fibrosis of the allograft and allograft loss if the expression levels of said miRNA samples are altered relative to a control level for each microRNA, and
- (d) treating the allograft recipient by administering an effective amount of a drug for treating fibrosis of the allograft and allograft loss.
Dependencies are inferred from the claim text.